Global Ulcerative Colitis Market Competitive Landscape, Top Market Segments, And Fastest Growing Regions
28 Jul, 2023
The global ulcerative colitis market size is expected to grow from $6.35 billion in 2022 to $6.84 billion in 2023 at a compound annual growth rate (CAGR) of 7.7%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The global ulcerative colitis market size is expected to reach $8.86 billion in 2027 at a CAGR of 6.7%.
Global Ulcerative Colitis Market Key Driver
The rising cost of healthcare is projected to drive the expansion of the ulcerative colitis market in the coming years. Health expenditure includes all spending on health-related services, family planning, nutrition, and emergency assistance, but excludes spending on drinking water and sanitation. Increased healthcare spending can help ulcerative colitis patients get better access to medical treatment and medicines. Hospitalization for ulcerative colitis can be costly, and hospital readmissions for flares can increase mortality and healthcare expenses.
Get a sample of the global ulcerative colitis market reportGlobal Ulcerative Colitis Market Segments
The global ulcerative colitis market is segmented:
1) By Drug Type: Anti-Inflammatory Drugs, Anti-TNF Biologics, Immunosuppressant, Calcineurin Inhibitors, Other Drug Types
2) By Disease Type: Ulcerative Proctitis, Proctosigmoiditis, Left-sided Colitis, Pancolitis or Universal Colitis, Fulminant Colitis
3) By Molecule Type: Biologics, Small Molecules
4) By Route of Administration: Oral, Injectables
5) By End-User: Hospital Pharmacies, Retail Pharmacies, Drug Store, Other End-User
6) By Geography: The regions covered in the ulcerative colitis market report are Asia-Pacific, Western Europe, Eastern Europe,North America, South America, Middle East, and Africa. Among these regions, North America accounts for the largest share in the global ulcerative colitis market.
Major Ulcerative Colitis Industry Players
Abbott Laboratories, AbbVie Inc., Ajinomoto Co. Inc., AstraZeneca PLC, Bausch Health Companies Inc., Eli-Lilly And Co., Johnson & Johnson, Index Pharmaceuticals Holdings AB, GlaxoSmithKline PLC, Merck & Co. Inc., Novartis AG, Pfizer Inc., Sanofi S.A., Allergan PLC, Bayer AG, BioLineRx Ltd., Celgene Corporation
Get the full global ulcerative colitis market report
Ulcerative Colitis Market Overview
Ulcerative colitis is a chronic inflammatory bowel disease (IBD) and is categorized as an autoimmune disorder in which the immune system attacks healthy tissue of the large intestine and causes inflammation on the superficial layer of the large intestine. It includes symptoms of diarrhea, weight loss, abdominal cramping, anemia, blood or pus in bowel movements, and others.
Ulcerative Colitis Global Market Report 2023 provides data on the global ulcerative colitis market such as market size, growth forecasts, segments and geographies, competitive landscape including leading competitors’ revenues, profiles and market shares. The ulcerative colitis market report identifies opportunities and strategies based on market trends and leading competitors’ approaches.